smithkline beckman corp said pursuing three point stragey will achieve pct annual increase operating earnings throughout remainder decade 1986 smithkline earned 521 mln dlrs dlrs per share revenues billion dlrs company said its annual report its nonpharmaceutical business will play major role meeting its earnings growth target and will fact grow faster its pharmaceutical business smithkline whose major product antiulcer medication tagamet said report intends improve earnings from existing products expand its product portfolio and optimize its financial resources bolster its position antiulcer market which tagamet has met stiff competition smithkline said its strategy develop over counter version tagamet bolstered two joint ventures with and pending venture japan smithkline also said its allergan inc eye and skin care products division can billion dlr organization next five years can grow more seven pct annually nondilutive acquisitions real possibility gavin herbert president eye and skin care product group said report 1986 allergan had worldwide sales 433 mln dlrs said its smith kline and french laboratories pharmaceuticals unit with 1986 sales billion dlrs will file for food and drug administration marketing approval for number cardiovascular agents including tissue plasminogen activator over next two years also said and sales force will pct larger 1987 with more 000 sales personnel smith kline also said its small clinical laboratory testing unit with 1986 sales 373 mln dlrs performs mln tests year and sees increases employee drug testing well testing for aids antibody smith kline said depending its share price and cost money may buy back more shares last three years has bought back about pct its shares smithkline begins year with new management team including its new chief operating officer george ebright reuter 